Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by ForexWhaleon Dec 19, 2018 10:36pm
46 Views
Post# 29138669

RE:RE:RE:RE:if no financing

RE:RE:RE:RE:if no financing Its a 5 million dollar worth company with no staff I am guessing who can reply to every email. Usually companies have PR departments and CEO is not responding directly as it can be agains the law as well for a public company.

Bashers will always find a way to talk this down. Fact is that they are reviewing quotes and thats about it. Presentation is being updated as well. My guess is they will update it with new partner name and its offline as they are not seeking quotes anymore.

Anyways. We can argue here all day and gain nothing. All the best with your strategy but I was and will stay long on this one purely based on latest NR's. My hope is to have a licensing out deal rather than just 2 million funding at 5 cents.
<< Previous
Bullboard Posts
Next >>